An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
Description
Potent neutralizing antibodies (nAbs) against SARS-CoV-2 are a promising therapeutic against the ongoing COVID-19 pandemic. However, the continuous emergence of neutralizing antibody escape variants makes it challenging for antibody therapeutics
